Copernicus Therapeutics Inc., of Cleveland, said it received U.S. Patent No. 6,281,005 for its automated nucleic acid compaction device.
Gene Therapy Systems Inc., of San Diego, said it was granted U.S. Patent No. 6,280,977 covering the method for generating transcriptionally active DNA fragments using the polymerase chain reaction.
Geron Corp., of Menlo Park, Calif., said it received U.S. Patent No. 6,261,836 covering claims directed to the gene that encodes human telomerase. Telomerase is an enzyme that can extend the life span of normal cells.
GPC Biotech AG, of Munich, Germany, said U.S. Patent No. 6,242,575, covering antibodies specifically immunoreactive with the p27 cell cycle inhibitory protein and a prognostic kit for detecting the p27 protein levels in cancer cells, was issued to the Memorial Sloan-Kettering Cancer Center in New York and the Fred Hutchinson Cancer Research Center in Seattle. GPC Biotech has an exclusive, worldwide license for the therapeutic and diagnostic applications.
Helix BioMedix Inc., of New Orleans, said it received U.S. Patent No. 6,255,282 titled ¿Lytic Peptides.¿ It covers methods of use of Helix proprietary compounds as agents for the therapeutic treatment, in humans and animals, of microbial infections and cancer. The patent also covers therapeutic uses in wound healing by boosting the immune system.
ILEX Oncology Inc., of San Antonio, said it was granted U.S. Patent No. 6,277,411 B1 titled ¿Pharmaceutical Formulation Containing DFMO for the Treatment of Cancer.¿ It cover¿s the company¿s controlled-release formulations of eflornithine.
Infectech Inc., of Sharon, Pa., said it received U.S. Patent No. 6,277,562 titled ¿A Method for Paraffinophilic Isolation and Identification From a Body Specimen.¿ It covers a method for detecting and killing non-tuberculosis mycobacteria and Pseudomonas.
Interleukin Genetics Inc., of Waltham, Mass., said it was granted U.S. Patent No. 6,251,598 for methods for predicting a patient¿s risk for severe septic shock following an infection.